Vertex Pharmaceuticals’ (VRTX) “Outperform” Rating Reaffirmed at William Blair
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...
Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day
Vertex Pharmaceuticals Inc. closed $108.22 short of its 52-week high ($519.88), which the company achieved on November 8th.
Moderna's mRNA Technology Looks Undervalued Despite Lower Covid Vaccine Demand
Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...
AFP1d
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor ...
Billed as nonaddictive, new pain pill could soon win FDA approval
A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove ...
Vertex Pharmaceuticals Incorporated (VRTX) CEO Reshma Kewalramani Hosts 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 10:30 AM ETCompany ParticipantsDr.
1 growth stock that could soar 105%, according to Wall Street experts
This Fool has his eye on an innovative growth stock that has plunged by 80% since early 2021. But what is so special about it ...
The Pharma Letter4d
Vertex out-licenses povetacicept to Zai Lab
US biopharma Vertex Pharmaceuticals has entered an exclusive collaboration and license agreement with China’s Zai Lab for the ...
The Massachusetts biotech industry rebounded in 2024. Can the momentum last?
The industry continues to face financial and regulatory headwinds, including high interest rates and uncertainty about ...
lifesciencesweden.se5d
FDA approves new cystic fibrosis therapy
A new treatment for cystic fibrosis has been approved by the U.S. Food and Drug Administration (FDA).
FiercePharma5d
With BIOSECURE in limbo, should BeiGene or Legend sell itself in 2025? Analysts weigh in
When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...
Lupin receives US FDA tentative approval for Ivacaftor Oral Granules
These granules, available in 25 mg, 50 mg, and 75 mg per unit dose packets, are a generic equivalent of Kalydeco Oral ...